Spanish biopharma company PharmaMar reported that its Plitidepsin drug has a “potent preclinical efficacy” against COVID-19. Referencing a peer-reviewed paper published in the journal Science, the company reported that the drug led to a 99% reduction in viral loads in the lungs of animals treated with Plitidepsin. The study’s authors wrote: “We believe that our data and initial positive results from PharmaMar’s clinical trial suggests that Plitidepsin should be strongly considered for expanded clinical trials for the treatment of COVID-19.”